Cargando…

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the trea...

Descripción completa

Detalles Bibliográficos
Autor principal:	Sluis-Cremer, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147682/ https://www.ncbi.nlm.nih.gov/pubmed/25089538 http://dx.doi.org/10.3390/v6082960

Ejemplares similares

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol
por: Figueiredo, Anna, et al.
Publicado: (2006)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
por: Paneth, Agata, et al.
Publicado: (2019)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

N(1),N(3)-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase
por: Novikov, Mikhail S., et al.
Publicado: (2013)

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors
por: Jiang, Xiangyi, et al.
Publicado: (2023)

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012)

What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?
por: Paneth, Agata, et al.
Publicado: (2017)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz
por: Jordaan, Maryam A, et al.
Publicado: (2017)

Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor–Based Antiretroviral Therapy in India
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2011)

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
por: Boyer, Paul L., et al.
Publicado: (2019)

Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase
por: Radzio, Jessica, et al.
Publicado: (2011)

Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance
por: Clutter, Dana S., et al.
Publicado: (2016)

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
por: Cha, Yu-Jung, et al.
Publicado: (2014)

Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors
por: Liu, Genyan, et al.
Publicado: (2018)

Large Multidomain Protein NMR: HIV-1 Reverse Transcriptase Precursor in Solution
por: Ilina, Tatiana V., et al.
Publicado: (2020)

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Karamchand, Sumanth, et al.
Publicado: (2016)

Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence
por: Schauer, Grant D., et al.
Publicado: (2014)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains
por: Liu, Yongjian, et al.
Publicado: (2020)

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
por: Yap, Soo-Huey, et al.
Publicado: (2007)

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
por: Lake, Jordan E., et al.
Publicado: (2015)

The RNA binding protein HuR does not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro
por: Ahn, Jinwoo, et al.
Publicado: (2010)

Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis
por: Bertagnolio, Silvia, et al.
Publicado: (2020)

Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase
por: Brehm, Jessica H., et al.
Publicado: (2012)

Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)
por: Brown, Jennifer A., et al.
Publicado: (2021)

Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach
por: Mansouri, Mahta, et al.
Publicado: (2023)

HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data
por: Tarasova, Olga, et al.
Publicado: (2018)

HIV-1 CRF08_BC mutants resistant to reverse transcriptase inhibitors
por: Wu, Hao, et al.
Publicado: (2014)

Retrospective analysis of the HIV-1 reverse transcriptase inhibitors’ resistance in Silesia, Poland
por: Smolen, Joanna, et al.
Publicado: (2011)

Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP
por: Jiao, Liyan, et al.
Publicado: (2012)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Approved HIV reverse transcriptase inhibitors in the past decade
por: Li, Guangdi, et al.
Publicado: (2022)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review
por: Tarasova, Olga, et al.
Publicado: (2018)

Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
por: Singh, Kamalendra, et al.
Publicado: (2014)

Aptamers that recognize drug-resistant HIV-1 reverse transcriptase
por: Li, Na, et al.
Publicado: (2008)

Aptamers that recognize drug-resistant HIV-1 reverse transcriptase
por: Li, Na, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jhl5ek0mh82ahbf3gi5h14if17